All News
Filter News
Found 153 articles
-
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
5/3/2022
Brickell Biotech, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Tuesday, May 17, 2022 at 10 a.m. Mountain Time with respect to all proposals described in Brickell’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 22, 2022.
-
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
5/3/2022
Brickell Biotech, Inc. announced that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics.
-
Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo
4/27/2022
Comera Life Sciences, Inc. today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person.
-
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
4/19/2022
Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.
-
Mineralys Therapeutics Appoints Adam Levy as Chief Financial Officer and Chief Business Officer
3/15/2022
Mineralys Therapeutics, Inc. today announced the appointment of Adam Levy as the company's new Chief Financial Officer (CFO) and Chief Business Officer (CBO).
-
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/15/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Study Results for Sofpironium Bromide Gel, 15% at the 2022 AAD Annual Meeting
3/10/2022
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), announced today that results from the US Phase 3 pivotal Cardigan I and Cardigan II studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients were selected for an oral presentation at the Late-Breaking Research session during the American Academy of Dermatology’s (AAD) 2022 Annual Meeting.
-
Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 15, 2022
3/8/2022
Brickell Biotech, Inc. announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15th.
-
STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors
2/14/2022
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors.
-
Palmer Hyperhidrosis Treatment Market: Primary Focal Hyperhidrosis Segment to Be Highly Attractive Segment
2/11/2022
Hyperhidrosis is a disorder that results in excessive sweating of palms, soles, or underarms. Palmer hyperhidrosis is excessive and uncontrollable hand sweating, and it is the most common type of hyperhidrosis.
-
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
2/4/2022
Investor Call Rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST to Discuss Combination between Comera Life Sciences, Inc. and OTR Acquisition Corp.
-
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
-
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inflammatory Diseases from Carna Biosciences
2/2/2022
Brickell Biotech, Inc. today announced that they have entered into a licensing agreement, whereby Brickell will have the exclusive, worldwide rights to develop and commercialize Carna’s portfolio of novel, potent, and orally available Stimulator of Interferon Genes (STING) antagonists.
-
Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.
1/31/2022
Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp., a publicly traded special purpose acquisition company, announced they have entered into a business combination agreement.
-
SCYNEXIS to Host Ibrexafungerp Hospital Pipeline Update Call and KOL Webcast for Investors on December 6
11/29/2021
SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a hospital pipeline update for its novel antifungal, ibrexafungerp, during a webcast on Monday, December 6, at 10 a.m. ET.
-
Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/9/2021
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
11/1/2021
Brickell Biotech, Inc., a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, announced that it will report its financial results for the third quarter, ended September 30, 2021.
-
Brickell Biotech Prices Public Offering of Common Stock
10/28/2021
Brickell Biotech, Inc. announced today the pricing of its previously announced underwritten public offering of 26,316,000 shares of its common stock at a price to the public of $0.38 per share.
-
Brickell Biotech Announces Proposed Underwritten Public Offering of Common Stock
10/27/2021
Brickell Biotech, Inc. announced today that it has commenced a proposed underwritten public offering of shares of its common stock.